ABSTRACT
Background Community-acquired pneumonia (CAP) is an essential consideration in patients presenting to primary care with respiratory symptoms; however, accurate diagnosis is difficult when clinical and radiologic examinations are not possible, such as during telehealth consultations.
Aim To develop and test a smartphone-based algorithm for diagnosing CAP without need for clinical examination or radiology inputs.
Design and Setting A prospective cohort study using data from subjects aged over 12 years presenting with acute respiratory symptoms to a hospital in Western Australia.
Method Five cough audio-segments were recorded and four patient-reported symptoms (fever, acute cough, productive cough, age) were analysed by the smartphone-based algorithm to generate an immediate diagnostic output for CAP. We recruited independent cohorts to train and test the accuracy of the algorithm.
Diagnostic agreement was calculated against the confirmed discharge diagnosis of CAP by specialist physicians. Specialist radiologists reported medical imaging.
Results The algorithm had high percent agreement (PA) with the clinical diagnosis of CAP in the total cohort (n=322, Positive PA=86%, Negative PA=86%, AUC=0.95); in subjects 22-65 years (n=192, PPA=86%, NPA=87%, AUC=0.94) and in subjects >65 years (n=86, PPA=86%, NPA=87.5%, AUC=0.94). Agreement was preserved across CAP severity: 85% (80/94) of subjects with CRB-65 scores 1-2, and 87% (57/65) with a score of 0, were correctly diagnosed by the algorithm.
Conclusion The algorithm provides rapid and accurate diagnosis of CAP. It offers improved accuracy over current protocols when clinical evaluation is difficult. It provides increased capabilities for primary and acute care, including telehealth services, required during the COVID-19 pandemic.
How this fits in?Diagnosis of community-acquired pneumonia (CAP) in the primary care setting relies upon the identification of clinical features or abnormal vital signs during a clinical examination. We have developed a smartphone-based algorithm which removes the requirement for in-person consultation and provides high-diagnostic agreement with specialist diagnosis of CAP. The algorithm requires the input of five cough-sound segments and four patient-reported symptoms and provides a result in less than one minute. With increasing momentum towards digital-first care under the NHS, tools such as this which allow remote deployment are likely to find increased merit.
Competing Interest Statement
PP, SC and UA are scientific advisors of ResApp Health (RAP). PP and UA are shareholders in RAP. UA was RAP's Chief Scientist. RAP is an Australian publicly listed company commercialising the technology under license from the University of Queensland, where UA is employed. UA is a named inventor of the UQ technology. VS and JW are employees of ResApp Health. NB, JB, CS, FP and PD declare no competing interests.
Clinical Trial
ACTRN12618001521213
Funding Statement
ResApp Health provided funding to support the Breathe Easy Program at JHC and UQ. Joondalup Health Campus provided office space, IT services and consumables in kind.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Human Research Ethics Committees of Princess Margaret Hospital (2015030EP), Joondalup Health Campus (1501), Curtin University (HRE20180016) and The University of Queensland (2015000395 2016.01.179). All participants, parents or guardians signed a consent to participate form.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The underlying codes are the property of ResApp Health and are not available. The datasets supporting the conclusion of this article are available on reasonable request from PP and JB. The cough recordings are not available but will be uploaded as an educational tool in the future.
